You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 10,532,047


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,532,047 protect, and when does it expire?

Patent 10,532,047 protects REZLIDHIA and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 10,532,047
Title:Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Abstract:The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
Inventor(s):Luke George P.
Assignee:FORMA Therapeutics, Inc.
Application Number:US16414716
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,532,047: A Detailed Analysis

Introduction

Patent 10,532,047, like any other patent, is a complex document that outlines the invention, its scope, and the claims that define its intellectual property boundaries. To analyze this patent, we need to delve into its claims, the patent landscape, and the relevant guidelines and tools provided by the USPTO.

Patent Overview

Patent Number and Title

United States Patent 10,532,047 is a utility patent that covers a specific invention. The title of the patent provides the first clue about the nature of the invention.

Inventors and Assignees

The inventors and assignees listed on the patent are crucial for understanding the ownership and the development history of the invention.

Filing and Grant Dates

The filing date and the grant date are important milestones that indicate when the invention was first disclosed and when it was officially recognized as a patent.

Claims Analysis

Claim Structure

The claims section of a patent is the most critical part, as it defines the scope of the invention. Claims are typically divided into independent and dependent claims. Independent claims stand alone and define the invention broadly, while dependent claims build upon the independent claims and provide additional details[3].

Claim Types

  • Independent Claims: These claims define the invention in its broadest terms and are essential for determining the patent's scope.
  • Dependent Claims: These claims narrow down the invention by adding specific details or limitations to the independent claims.

Claim Language and Scope

The language used in the claims is precise and technical. For example, if a claim involves AI technology, it must integrate the abstract idea into a practical application to be considered patent-eligible. This is in line with the 2024 USPTO guidance update, which emphasizes the need for claims to impose meaningful limits on judicial exceptions and to provide concrete technological improvements[1].

Patent Eligibility Under USPTO Guidelines

Judicial Exceptions and Practical Applications

The 2024 USPTO guidance update clarifies that claims must integrate judicial exceptions (such as abstract ideas or mathematical models) into practical applications. For instance, a claim that merely uses a mathematical model to manipulate data without a specific practical application would not be patent-eligible. However, if the claim specifies the use of the data in a real-time speech recognition system to enhance accuracy, it would be considered patent-eligible[1].

AI-Assisted Inventions

The update also clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution[1].

Patent Landscape and Prior Art

Searching Prior Art

To understand the patent landscape, it is crucial to conduct a thorough search of prior art. The USPTO provides several tools for this purpose, including the Patent Public Search tool, Global Dossier, and the Public Search Facility. These resources help in identifying existing patents and published patent applications that may be relevant to the invention[4].

International Patent Databases

Searching international patent databases, such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO), is also essential to ensure that the invention is novel and non-obvious on a global scale[4].

Practical Applications and Technological Improvements

Real-World Applications

Highlighting the real-world applications of the claimed method or system is crucial for demonstrating patent eligibility. For example, if a claim specifies the use of separated audio components in a real-time speech recognition system to enhance the accuracy of voice commands, it provides a tangible benefit and meets the criteria for patent eligibility[1].

Technological Improvements

The claimed invention must offer a clear technological improvement. This could be in the form of improved noise reduction in audio processing, enhanced accuracy in real-time speech recognition, or overall better performance in voice-controlled systems[1].

Patent Scope Metrics

Independent Claim Length and Count

Research suggests that the scope of a patent can be measured using metrics such as independent claim length and independent claim count. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes[3].

Challenges and Considerations

Overly Broad Claims

One of the challenges in patent drafting is avoiding overly broad claims that may lead to section 101 rejections. The 2024 USPTO guidance update provides examples and detailed eligibility analysis to help practitioners draft claims that are more likely to avoid such rejections[1].

Litigation and Licensing Costs

Patents with unclear or overly broad claims can lead to increased litigation and licensing costs, which can diminish the incentives for innovation. Therefore, it is essential to ensure that the claims are clear, specific, and well-defined[3].

Key Takeaways

  • Claims Must Integrate Judicial Exceptions: Claims must integrate abstract ideas or mathematical models into practical applications to be patent-eligible.
  • AI-Assisted Inventions: The use of AI in the method of invention development does not impact subject matter eligibility.
  • Practical Applications: Highlighting real-world applications of the claimed method or system is crucial for demonstrating patent eligibility.
  • Technological Improvements: The claimed invention must offer clear technological improvements.
  • Patent Scope Metrics: Independent claim length and count can be used to measure patent scope.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patent eligibility?

The 2024 USPTO guidance update refines and clarifies the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications and ensuring AI-assisted inventions are evaluated on equal footing with other technologies[1].

How do you determine if a claim is patent-eligible under the new guidelines?

A claim is patent-eligible if it integrates a judicial exception into a practical application, imposes meaningful limits on the exception, and provides a concrete technological improvement[1].

What tools does the USPTO provide for searching prior art?

The USPTO provides tools such as the Patent Public Search tool, Global Dossier, Public Search Facility, and access to international patent databases to search prior art[4].

Why is it important to avoid overly broad claims in patent drafting?

Overly broad claims can lead to section 101 rejections and increase litigation and licensing costs, which can diminish the incentives for innovation[3].

How can the scope of a patent be measured?

The scope of a patent can be measured using metrics such as independent claim length and independent claim count, which have explanatory power for several correlates of patent scope[3].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. U.S. Patent Small Claims Court - ACUS
  3. Patent Claims and Patent Scope - SSRN
  4. Search for patents - USPTO - USPTO

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,532,047

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rigel Pharms REZLIDHIA olutasidenib CAPSULE;ORAL 215814-001 Dec 1, 2022 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,532,047

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark 3720442 ⤷  Subscribe
European Patent Office 3720442 ⤷  Subscribe
European Patent Office 4215197 ⤷  Subscribe
Spain 2941079 ⤷  Subscribe
Finland 3720442 ⤷  Subscribe
Croatia P20230168 ⤷  Subscribe
Hungary E061331 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.